View Older Stories View More Recent Stories
-
Travere Therapeutics (TVTX) Reiterated at Hold by Stifel After FDA Asks for More Info
-
Stifel on Travere Therapeutics (TVTX): 'FSGS Increases Risk of CRL, Though Delay/Approval Still Possible'
-
Travere reports record Q4 FILSPARI sales of $103 million
-
FDA;s messaging is positive for Travere Therapeutics (TVTX) - Cantor Fitzgerald
-
Jefferies lists 5 biotech M&A candidates for 2026
-
Travere Therapeutics (TVTX) PT Raised to $48 at Citi, New Catalyst Watch
-
Travere Therapeutics (TVTX) Tops Q3 EPS by 88c
-
KDIGO guidelines include FILSPARI for IgA nephropathy treatment
-
H.C. Wainwright Reiterates Buy Rating on Travere Therapeutics (TVTX)
-
H.C. Wainwright Reiterates Buy Rating on Travere Therapeutics (TVTX)
-
H.C. Wainwright on Travere Therapeutics (TVTX): 'We see adapted REMS as competitive advantage. We view this as positive news for Travere, particularly as it competes with Novartis’ (NVO; not rated)
-
Jefferies on Travere Therapeutics (TVTX): 'AdCom Cancellation Clear Positive In Our View Setting Stage For Likely Approval'
-
Stifel Reiterates Hold Rating on Travere Therapeutics (TVTX)
-
Cantor Fitzgerald Comments on Travere Therapeutics (TVTX) Amid Shares Gaining 22pct
-
FDA cancels advisory committee for Travere's FILSPARI in rare kidney disease
-
H.C. Wainwright Reiterates Buy Rating on Travere Therapeutics (TVTX)
-
Travere Therapeutics (TVTX) PT Raised to $47 at H.C. Wainwright
-
Travere Therapeutics (TVTX) PT Lowered to $20 at Stifel
-
Travere Therapeutics (TVTX) Tops Q2 EPS by 16c
-
H.C. Wainwright Assumes Travere Therapeutics (TVTX) at Buy
-
Travere Therapeutics (TVTX) PT Lowered to $32 at Citi, Adds 90d Upside Catalyst Watch
-
Travere Therapeutics (TVTX) call put ratio 1 call to 2.8 puts with a focus on June 15 and 17.50 puts
-
Stifel Reiterates Hold Rating on Travere Therapeutics (TVTX)
-
Cantor Fitzgerald Reiterates Overweight Rating on Travere Therapeutics (TVTX)
-
Citi on Travere Therapeutics (TVTX): 'we would buy the dip', Opens 30-Day Upside Catalyst Call
-
Travere Therapeutics (TVTX) Announces FDA Acceptance of sNDA for FILSPARI in FSGS
-
Travere Therapeutics (TVTX) Tops Q1 EPS by 36c
-
Travere Therapeutics (TVTX) and CSL Vifor Announce Standard EU Approval of FILSPARI (sparsentan) for IgA Nephropathy
-
Cantor Fitzgerald Reiterates Overweight Rating on Travere Therapeutics (TVTX)
-
Cantor Fitzgerald Reiterates Overweight Rating on Travere Therapeutics (TVTX)
-
Travere Therapeutics (TVTX) PT Raised to $47 at Canaccord Genuity
-
Cantor Fitzgerald Reiterates Overweight Rating on Travere Therapeutics (TVTX)
-
Smid cap biotech investors must stop chasing binary events says Cantor Fitzgerald
-
Travere Therapeutics (TVTX) to Present New FILSPARI Data at the National Kidney Foundation Spring Clinical Meetings 2025
-
Travere Therapeutics (TVTX) Submits sNDA to FDA for Approval of FILSPARI
-
Travere Therapeutics (TVTX) PT Raised to $35 at Citi
-
Travere Therapeutics (TVTX) Tops Q4 EPS by 17c
-
Travere Therapeutics (TVTX) PT Raised to $32 at Scotiabank
-
Travere Therapeutics (TVTX) PT Raised to $45 at Canaccord Genuity
-
Travere Therapeutics (TVTX) call put ratio 2.7 calls to 1 put with a focus on a spreader of March 20 and 30 calls
-
JPMorgan is out with its 2025 outlook for biotech stocks
-
JPM just added these stocks to its Analyst Focus List - giving one 148% upside
-
Travere Therapeutics (TVTX) Prices 7.81M Share Offering at $16/sh
-
Travere Therapeutics (TVTX) Announces Proposed Share Offering
-
Travere Therapeutics (TVTX) PT Raised to $33 at Evercore ISI
-
TD Cowen Reiterates Buy Rating on Travere Therapeutics (TVTX)
-
Wells Fargo Upgrades Travere Therapeutics (TVTX) to Overweight
-
4 biotech stocks to own to benefit from key Q4 catalysts
-
Travere Therapeutics (TVTX) and CSL Vifor Announce Swissmedic Approval of FILSPARI
-
Wells Fargo Reiterates Equal Weight Rating on Travere Therapeutics (TVTX)

